Another four lots of a diabetes drug recalled for having too much of a carcinogen
Nostrum Laboratories announced Monday evening and Tuesday morning that four lots of its version of Type 2 diabetes drug metformin have too much of the carcinogen NDMA.
Nostrum becomes the latest of many drug makers, most recently Marksans Pharma Limited of India last month, to recall their metformin because the NDMA (N-Nitrosodimethylamine) content surpasses the FDA’s daily limit.
This covers 100-tablet bottles of 750 mg Metformin Hydrochloride Extended Release Tablets, lot Nos. MET200101 and MET200301; and 500 mg Metformin Hydrochloride Extended Release Tablets, lot Nos. MET100201 and MET100401. All recalled bottles have an expiration date of 05/2022.
Consumers should keep taking their metformin until their doctor or another medical professional comes up with another course of treatment.
Consumers with medical questions regarding the recall can email Nostrum at quality@nostrumpharma.com or call the company at 816-308-4941 Monday through Friday, 9 a.m. to 6 p.m., Eastern time.
If this or any other drug causes a medical problem, after notifying a medical professional, let the FDA know via its MedWatch Adverse Event page or by filling out a form you can get by calling 800-332-1088.
37 lots of a mouthwash have been recalled for a possible bacterial contamination
Second company in 3 days recalls diabetes medicine for having too much of a carcinogen
More diabetes medicine recalled after testing finds too much carcinogen content
